Receptor News and Research

RSS

Weight-loss drugs linked to preterm birth risk in women with pre-existing diabetes

Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes.

17 Mar 2026

Implantable device boosts immune cells to fight cancer effectively

Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease.

17 Mar 2026

Tailored prediabetes treatment may better prevent Type 2 diabetes

A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, tailored prevention approach for those with the highest risk of developing Type 2 diabetes, according to preliminary research presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026.

17 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

Exercise cuts 'chemo brain' and fatigue in cancer patients

Implementing a simple exercise plan during chemotherapy may ease cognitive impairment and fatigue, promoting better health outcomes for cancer patients.

17 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

New CAR-NKT cell therapy shows promise against aggressive endometrial cancer

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades.

16 Mar 2026

Researchers develop targeted delivery system for poorly soluble cancer drugs

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high therapeutic efficacy.

16 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

Kyoto University unveils noninvasive assessment for diabetes

In type 1 diabetes, the immune system starts to destroy insulin-producing beta cells in the pancreas. Progressive loss of these cells destabilizes the body's glucose levels and drives the course of the disease, so preserving or restoring beta cell mass is a central treatment goal.

13 Mar 2026

Gut microbes may drive memory decline during aging by disrupting vagal brain signaling

Researchers identified in mice a microbiome–gut–brain pathway in which age-associated changes in gut microbes increase medium-chain fatty acids that impair vagal sensory signaling and hippocampal activity. These interoceptive disruptions weaken memory formation, revealing a microbial mechanism that contributes to cognitive decline during aging.

12 Mar 2026

Study links prior authorization to delayed heart failure prescriptions

Prior authorization, a process that requires physicians to obtain approval from health care insurers before certain treatments are covered, may keep patients from filling prescriptions for two critical heart failure drugs, a new study shows.

12 Mar 2026

Does coffee disrupt sleep? Large population study suggests the impact may be minimal

A large cross-sectional analysis of 25,381 Swedish adults aged 50–64 found that habitual coffee consumption showed only very weak associations with sleep quality and daytime sleepiness. Genetic analyses confirmed known coffee-related variants and suggested that long-term caffeine exposure may lead to adaptation in the brain’s adenosine signaling system.

11 Mar 2026

Researchers identify mechanism explaining chemical disruption of sex hormones

Researchers at the University of Oulu have identified a previously unknown mechanism in humans that may explain why certain medicines and environmental chemicals disrupt the balance of sex hormones.

11 Mar 2026

Simplified nanoparticles "educate" the immune system to find and destroy disease-causing cells

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout the body.

11 Mar 2026

How the aging gastrointestinal tract drives age-related cognitive decline

We become forgetful as we age. This is often seen as a universal truth, but in fact it is far from universal: some people remain incredibly sharp at 100 years old, while others experience memory loss starting in middle age.

11 Mar 2026

Marburg virus enters human cells far more efficiently than Ebola

In a new study published in Nature, University of Minnesota researchers found that the Marburg virus, one of the world's deadliest pathogens with an average 73% fatality rate, is unusually efficient at getting inside human cells.

11 Mar 2026

New review reveals complex polygenic architecture underlying common epilepsies

An insightful mini-review published in Genomic Psychiatry synthesizes the rapidly expanding landscape of molecular genetic research on common epilepsies, assembling evidence from genome-wide association studies, whole-exome sequencing projects, and advanced statistical modeling to illuminate the polygenic architecture that underpins these heterogeneous neurological disorders.

10 Mar 2026

Wegovy linked to higher risk of eye stroke and vision loss

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

10 Mar 2026